Novartis: Neoplasms trials

The registry lists 121 Neoplasms studies with Novartis as lead sponsor. 2 are open to participants now and 40 have results posted.

Phase 1 60Phase 2 40Phase 3 18Phase 4 7No phase 4(a study in two phases counts in both)

Studies

Page 1 of 2. Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Study of [177Lu]Lu-DWJ155 and [68Ga]Ga-DWJ155 in Patients With Solid TumorsRecruitingNCT07660055Phase 1
• A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and LymphomasRecruitingNCT04104776Phase 1/2
• 68Ga-PSMA-R2 in Patients With Biochemical Relapse (BR) and Metastatic Prostate Cancer (mPCa)CompletedNCT03490032Phase 1/2Results posted
• Study Assessing the Efficacy and Safety of Alpelisib Plus Fulvestrant in Men and Postmenopausal Women With Advanced Breast Cancer Which Progressed on or After Aromatase Inhibitor Treatment.CompletedNCT02437318Phase 3Results posted
• Study of Efficacy and Safety of LEE011 in Men and Postmenopausal Women With Advanced Breast Cancer.CompletedNCT02422615Phase 3Results posted
• Study of Prophylactic Octreotide to Prevent or Reduce the Frequency and Severity of Diarrhoea in Subjects Receiving Lapatinib With Capecitabine for the Treatment of Metastatic Breast CancerTerminatedNCT02294786Phase 2Results posted
• LEE011 for Patients With CDK4/6 Pathway Activated Tumors (SIGNATURE)CompletedNCT02187783Phase 2Results posted
• Study to Investigate Safety, Pharmacokinetic (PK), Pharmacodynamic (PD) and Clinical Activity of Trametinib in Subjects With Cancer or Plexiform Neurofibromas and Trametinib in Combination With Dabrafenib in Subjects With Cancers Harboring V600 MutationsCompletedNCT02124772Phase 1/2Results posted
• An Open Label Multi-center Extension Study to Evaluate Long-term Safety/ Tolerability of Dovitinib in Patients With Solid Tumors Who Continue to Receive Treatment With Dovitinib (TKI258) in Novartis-sponsored Single Agent Dovitinib Studies Which Fulfilled the Requirements for the Primary ObjectiveCompletedNCT02116803Phase 2/3Results posted
• Study to Investigate the Objective Response Rate of Dabrafenib in Combination With Trametinib in Subjects With BRAF V600 Mutation-Positive MelanomaCompletedNCT02083354Phase 2Results posted
• Efficacy and Safety of the Combination Therapy of Dabrafenib and Trametinib in Subjects With BRAF V600E- Mutated Rare CancersCompletedNCT02034110Phase 2Results posted
• Study to Collect and Assess Long-term Safety of Everolimus in Patients Who Are on Everolimus Treatment in a Novartis-sponsored Study and Are Benefiting From the Treatment as Judged by the Investigator.CompletedNCT02017860Phase 2Results posted
• Nilotinib Roll-over Protocol for Patients in Novartis-sponsored Nilotinib Study and Benefiting From Nilotinib TreatmentCompletedNCT01863745Phase 2Results posted
• BKM120 for Patients With PI3K-activated TumorsCompletedNCT01833169Phase 2Results posted
• Everolimus Roll-over Protocol for Patients Who Have Completed a Previous Novartis-sponsored Everolimus Study.CompletedNCT01789281Phase 4Results posted
• BRAF/MEK/EGFR Inhibitor Combination Study in Colorectal Cancer (CRC)CompletedNCT01750918Phase 1/2Results posted
• An Open Label Study of Postmenopausal Women With Oestrogen Receptor Positive Locally Advanced or Metastatic Breast Cancer Treated With Everolimus (RAD001) With Exemestane, With Exploratory Epigenetic Marker AnalysisCompletedNCT01743560Phase 4Results posted
• Phase I Study of LDK378 in Pediatric, Malignancies With a Genetic Alteration in Anaplastic Lymphoma Kinase (ALK)CompletedNCT01742286Phase 1Results posted
• Dabrafenib With Trametinib in the Adjuvant Treatment of High-risk BRAF V600 Mutation-positive Melanoma (COMBI-AD).CompletedNCT01682083Phase 3Results posted
• Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous MelanomaCompletedNCT01597908Phase 3Results posted
• Everolimus Post Pazopanib Treatment in Metastatic or Advanced Renal Cell CarcinomaTerminatedNCT01545817Phase 2Results posted
• Continuation Study of the Oral AKT Inhibitor GSK2110183CompletedNCT01531894Phase 2Results posted
• Ofatumumab Plus Bendamustine in Frontline and Relapsed Chronic Lymphocytic Leukaemia (CLL)CompletedNCT01520922Phase 2Results posted
• Multi-level Evaluation of Chemotherapy-induced Febrile Neutropenia Prophylaxis, Outcomes, and Determinants With Granulocyte-colony Stimulating FactorCompletedNCT01459653Results posted
• A Phase II Study to Evaluate the Efficacy of TKI258 for the Treatment of Patients With FGFR2 Mutated or Wild-type Advanced and/or Metastatic Endometrial CancerCompletedNCT01379534Phase 2Results posted
• GSK1120212 Rollover StudyTerminatedNCT01376310Phase 2Results posted
• Study of Selective BRAF Kinase Inhibitor Dabrafenib Monotherapy Twice Daily and in Combination With Dabrafenib Twice Daily and Trametinib Once Daily in Combination Therapy in Subjects With BRAF V600E Mutation Positive Metastatic (Stage IV) Non-small Cell Lung Cancer.CompletedNCT01336634Phase 2Results posted
• Ofatumumab vs Physician's Choice in Subjects With Bulky Fludarabine-Refractory Chronic Lymphocytic LeukemiaCompletedNCT01313689Phase 3Results posted
• Efficacy of Nilotinib in Adult Patients With Gastrointestinal Stromal Tumors Resistant to Imatinib and Sunitinib.CompletedNCT01289028Phase 3Results posted
• A Study to Evaluate Pazopanib as an Adjuvant Treatment for Localized Renal Cell Carcinoma (RCC)CompletedNCT01235962Phase 3Results posted
• Ofatumumab Bendamustine Combination Compared With Bendamustine Monotherapy in Indolent B-cell NHL Unresponsive to RituxtherapyTerminatedNCT01077518Phase 3Results posted
• Investigate Safety, Pharmacokinetics and Pharmacodynamics of GSK2118436 & GSK1120212CompletedNCT01072175Phase 2Results posted
• Patient Preference Study of Pazopanib Versus Sunitinib in Advanced or Metastatic Kidney CancerCompletedNCT01064310Phase 3Results posted
• Lapatinib in Combination With VinorelbineCompletedNCT01013740Phase 2Results posted
• Continued HER2 Suppression With Lapatinib Plus Trastuzumab Versus Trastuzumab AloneTerminatedNCT00968968Phase 3Results posted
• Ofatumumab Added to Fludarabine-Cyclophosphamide vs Fludarabine-Cyclophosphamide Combination in Relapsed Subjects With Chronic Lymphocytic LeukemiaCompletedNCT00824265Phase 3Results posted
• Ofatumumab + Chlorambucil vs Chlorambucil Monotherapy in Previously Untreated Patients With Chronic Lymphocytic LeukemiaTerminatedNCT00748189Phase 3Results posted
• LOGiC - Lapatinib Optimization Study in ErbB2 (HER2) Positive Gastric Cancer: A Phase III Global, Blinded Study Designed to Evaluate Clinical Endpoints and Safety of Chemotherapy Plus LapatinibCompletedNCT00680901Phase 3Results posted
• Efficacy and Safety Study of Panobinostat in Participants With Metastatic Hormone Refractory Prostate CancerCompletedNCT00667862Phase 2Results posted
• Everolimus and Octreotide in Patients With Advanced Carcinoid TumorCompletedNCT00412061Phase 3Results posted
• Safety/Efficacy of Everolimus in Adults With Advanced Pancreatic Neuroendocrine Cancer Not Responsive to ChemotherapyCompletedNCT00363051Phase 2Results posted
• Lapatinib for Brain Metastases In ErbB2-Positive Breast CancerCompletedNCT00263588Phase 2Results posted
• A Study of Safety and Efficacy of KFA115 Alone and in Combo With Pembrolizumab in Patients With Select Advanced CancersActive, not recruitingNCT05544929Phase 1
• A Phase I/II Study of DYP688 in Patients With Metastatic Uveal Melanoma and Other GNAQ/11 Mutant MelanomasActive, not recruitingNCT05415072Phase 1/2
• Study of 225Ac-PSMA-617 in Men With PSMA-positive Prostate CancerActive, not recruitingNCT04597411Phase 1
• [177Lu]-NeoB in Patients With Advanced Solid Tumors and With [68Ga]-neoB Lesion UptakeCompletedNCT03872778Phase 1/2
• 177Lu-PSMA-R2 in Patients With PSMA Positive Progressive, Metastatic, Castration Resistant Prostate CancerTerminatedNCT03490838Phase 1
• A Study of PDR001 in Combination With CJM112, EGF816, Ilaris® (Canakinumab) or Mekinist® (Trametinib)CompletedNCT02900664Phase 1
• Roll-over Study to Allow Access to Certinib (LDK378) for Patients Who Are on Ceritinib Treatment in a Novartis-sponsored StudyActive, not recruitingNCT02584933Phase 4
• Study of Safety and Efficacy of LEE011 and Ceritinib in Patients With ALK-positive Non-small Cell Lung Cancer.CompletedNCT02292550Phase 1
• Study of Afuresertib Combined With Paclitaxel in Gastric CancerCompletedNCT02240212Phase 1
• A Study Conducted in Subjects With Relapsed/Refractory Multiple Myeloma (MM); to Determine Dose of Afuresertib in Combination With Carfilzomib (Part 1) and to Investigate the Safety, Pharmacokinetic and Clinical Activity of the Combination Compared With Carfilzomib Alone (Part 2)TerminatedNCT02235740Phase 1
• Study of Safety and Efficacy of INC280 and Cetuximab, in Adult c-MET Positive mCRC and HNSCC Patients After Progression on Cetuximab or Panitumumab TherapyTerminatedNCT02205398Phase 1
• Study of Afuresertib Monotherapy in Japanese Relapsed Multiple Myeloma PatientsTerminatedNCT02177682Phase 1
• Study of Safety and Efficacy of Alpelisib With Everolimus or Alpelisib With Everolimus and Exemestane in Advanced Breast Cancer Patients, Renal Cell Cancer and Pancreatic TumorsCompletedNCT02077933Phase 1
• A Study to Evaluate the Potential Benefit of the Addition of BYL719 to Paclitaxel in the Treatment of Breast Cancer and Head-and-neck CancerCompletedNCT02051751Phase 1
• Safety and Tolerability of Oral LCL161 in Japanese Adult Patients With Advanced Solid TumorsCompletedNCT01968915Phase 1
• A Phase I Study of LJM716 in Japanese Patients With Advanced Solid TumorsCompletedNCT01911936Phase 1
• A Phase I Study of LEE011 in Asian PatientsCompletedNCT01898845Phase 1
• Drug-drug Interaction Study of Ofatumumab With Bendamustine in Subjects With Indolent B-cell Non-Hodgkin's LymphomaCompletedNCT01691807Phase 1
• Pharmacokinetic Drug-drug Interaction Study of Dovitinib (TKI258) in Patients With Advanced Solid TumorsCompletedNCT01596647Phase 1
• A Phase II Study to Evaluate Efficacy and Safety of Dovitinib (TKI258) in Advanced Scirrhous Gastric Carcinoma PatientsCompletedNCT01576380Phase 2
• Phase I Dose Escalating Study of TKI258CompletedNCT01471548Phase 1
• Bioequivalence of 2 Formulations of TKI258 in Patients With Advanced Solid TumorsCompletedNCT01421004Phase 1
• Drug Use Investigation for ARRANON G (Nelarabine) Injection 250mgCompletedNCT01376115
• Drug Use Investigation for TYKERB Tablet (All Case Investigation)CompletedNCT01332396
• Safety and Pharmacokinetics of ASA404 When Given Together With Fluvoxamine, a Selective Serotonin Receptor Reuptake Inhibitor and CYP1A2 InhibitorTerminatedNCT01299415Phase 1
• A Trial of Oral BEZ235 and BKM120 in Combination With Paclitaxel With or Without TrastuzumabCompletedNCT01285466Phase 1
• Glivec® Plus m-FOLFOX Avastin® in Advanced Colorectal CancerTerminatedNCT01271166Phase 1
• Safety of CHIR-258 (TKI258) in Advanced Solid TumorsTerminatedNCT01270906Phase 1
• A Rollover Study to Provide Continued Treatment With GSK2118436 to Subjects With BRAF Mutation-Positive TumorsCompletedNCT01231594Phase 1
• Study for Women With Platinum Resistant Ovarian Cancer Evaluating EC145 in Combination With Doxil® (PROCEED)TerminatedNCT01170650Phase 3
• Role of Early Versus Late Switch to Lapatinib-Capecitabine (TYCO)CompletedNCT01160094
• Bioavailability and Food Effect Study of TKI258 (CSF Capsule vs. FMI Tablet) in Adult Patients With Advanced Solid TumorsCompletedNCT01155713Phase 1
• Safety and Efficacy of LCL161 in Patients With Solid TumorsCompletedNCT01098838Phase 1
• Bioavailability and Food Effect Study of TKI258 (CSF Capsules vs. FMI Capsules)in Adult Patients With Advanced Solid TumorsCompletedNCT01030055Phase 1
• Extension Study of EC145 (Vintafolide) for Subjects Enrolled in a Previous Study With EC145 (MK-8109-010)CompletedNCT01002924Phase 2
• A Study of HSP990 Administered by Mouth in Adult Patients With Advanced Solid TumorsCompletedNCT00879905Phase 1
• Study of EC0489 for the Treatment of Refractory or Metastatic TumorsCompletedNCT00852189Phase 1
• Continuation Study of Lapatinib Monotherapy or Lapatinib in Combination With Other Anti-cancer AgentsCompletedNCT00790816Phase 1
• Phase I Study to Determine the Maximum Tolerate Dose (MTD) of BGT226 in Advanced Solid Tumors in JapanTerminatedNCT00742105Phase 1
• Dose-escalating Study of LBH589 in Adult Patients With Advanced Solid TumorsCompletedNCT00739414Phase 1
• Platinum Resistant Ovarian Cancer Evaluation of Doxil and Vintafolide (MK-8109, EC145) Combination Therapy (8109-009, EC-FV-04)CompletedNCT00722592Phase 2
• A Dose Finding Study With I.V. Panobinostat (LBH589), Docetaxel, and Prednisone in Patients With Hormone Refractory Prostate CancerCompletedNCT00663832Phase 1
• A Phase I/II Study of BEZ235 in Patients With Advanced Solid Malignancies Enriched by Patients With Advanced Breast CancerCompletedNCT00620594Phase 1
• A Study to Investigate the Effect of Food on Oral LBH589 Absorption in Patients With Advanced Solid TumorsCompletedNCT00570284Phase 1
• Study of Vintafolide (MK-8109, EC145) in Participants With Progressive Adenocarcinoma of the Lung (MK-8109-008, EC-FV-03)CompletedNCT00511485Phase 2
• Study of Vintafolide (MK-8109, EC145) in Participants With Advanced Ovarian and Endometrial Cancers (MK-8109-007, EC-FV-02)CompletedNCT00507741Phase 2
• A Study to Investigate the Effects of Ketoconazole on LBH589 in Patients With Advanced Solid TumorsCompletedNCT00503451Phase 1
• A Phase II Study of EC17 (Folate-hapten Conjugate) in Patients With Progressive Metastatic Renal Cell CarcinomaTerminatedNCT00485563Phase 2
• The Effects of Patupilone on the Pharmacokinetics and Pharmacodynamics of Warfarin in Patients With Advanced MalignanciesTerminatedNCT00468260Phase 1
• Evaluate the Effects of Patupilone on the Pharmacokinetics and Pharmacodynamics of Warfarin in Patients With Advanced MalignanciesCompletedNCT00448396Phase 1
• Evaluate the Effects of Patupilone on the Pharmacokinetics of Midazolam and Omeprazole in Patients With Advanced Malignancies (Extension)WithdrawnNCT00442741Phase 1
• Study of EC0225 for the Treatment of Refractory or Metastatic TumorsCompletedNCT00441870Phase 1
• Patients Completing Core Protocol (CAMN107A2103), Exhibiting Stable Disease (SD), Partial Response (PR) or Complete Response (CR) to Nilotinib in Combination With ImatinibCompletedNCT00441155Phase 1
• Assessment of Pain and Quality of Life in Breast and Prostate Cancer Patients With Bone MetastasesCompletedNCT00434317Phase 4
• Combination Trial of Patupilone and Carboplatin in Adult Patients With Advanced Solid TumorsCompletedNCT00426582Phase 1
• A Study of Patupilone in Patients With Advanced Solid Tumors and Varying Degrees of Hepatic FunctionCompletedNCT00421044Phase 1
• Evaluate the Effects of Patupilone on the Pharmacokinetics of Midazolam and Omeprazole in Patients With Advanced MalignanciesCompletedNCT00420615Phase 1
• A Study of Patupilone in Patients With Advanced Solid Tumors and Varying Degrees of Hepatic FunctionCompletedNCT00420524Phase 1